Fig. 1: Overall experimental design for biomarker model development. | Nature Communications

Fig. 1: Overall experimental design for biomarker model development.

From: Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma

Fig. 1

Large-scale DIA-based proteomics was used to select HCC-related biomarker candidates, which were then validated in an independent validation cohort using PRM-based targeted proteomic approach. HCC diagnosis models were constructed based on machine learning and the efficacy of the models for HCC risk prediction was assessed through prospective long-term follow-up of LC patients.

Back to article page